Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction
暂无分享,去创建一个
Jian Yu | Lin Zhang | J. Tong | Suisui Hao | Anupma Jha | Xiaoyan Tan | Xinyan Lu | Kaylee Ermine | Zhaojin Liu | Jingshan Tong
[1] Jian Yu,et al. BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade , 2021, Oncogene.
[2] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[3] Xiang Guo,et al. The application and prospect of CDK4/6 inhibitors in malignant solid tumors , 2020, Journal of Hematology & Oncology.
[4] G. Rosner,et al. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). , 2018, Leukemia research.
[5] C. Austin,et al. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response , 2018, Oncotarget.
[6] W. Tap,et al. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. , 2018, Cancer cell.
[7] Gen Sheng Wu,et al. Developing TRAIL/TRAIL death receptor-based cancer therapies , 2018, Cancer and Metastasis Reviews.
[8] R. Mesa,et al. Combined venetoclax and alvocidib in acute myeloid leukemia , 2017, Oncotarget.
[9] W. El-Deiry,et al. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia , 2017, Cell cycle.
[10] P. Sicinski,et al. Cell cycle proteins as promising targets in cancer therapy , 2017, Nature Reviews Cancer.
[11] Jian Yu,et al. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation , 2016, Oncogene.
[12] M. Malumbres,et al. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases , 2016, Nature Reviews Molecular Cell Biology.
[13] A. Letai,et al. Mitochondria-Judges and Executioners of Cell Death Sentences. , 2016, Molecular cell.
[14] Agnieszka K. Witkiewicz,et al. The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.
[15] Jian Yu,et al. BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs , 2014, Proceedings of the National Academy of Sciences.
[16] Jian Yu,et al. TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity , 2014, Oncotarget.
[17] E. Chu. An update on the current and emerging targeted agents in metastatic colorectal cancer. , 2012, Clinical colorectal cancer.
[18] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[19] M. Chen,et al. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. , 2010, Surgical oncology.
[20] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[21] A. Ashkenazi,et al. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists , 2008, Nature Reviews Drug Discovery.
[22] J. Pietenpol,et al. The jury is in: p73 is a tumor suppressor after all. , 2008, Genes & development.
[23] Jian Yu,et al. Downregulation of Dkk3 activates β-catenin/TCF-4 signaling in lung cancer , 2008 .
[24] K. Kinzler,et al. Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.
[25] S H Kim,et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.
[26] I. Krantz,et al. KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.
[27] L Meijer,et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.